NCT02738801 - Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

May 2, 2017

Study Completion Date

May 2, 2017

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

GLPG1690 600 mg QD

GLPG1690 capsules, administered at a dose of 600 mg, orally QD

DRUG

Placebo QD

Matching placebo capsules, administered orally QD

Trial Locations (8)

Municipal Clinical Hospital # 6, Dnipropetrovsk

Kharkov City Clinical Hospital # 13, Kharkiv

F.G. Yanovskyy Institute of Phthisiatry and Pulmonology 1, Kiev

F.G. Yanovskyy Institute of Phthisiatry and Pulmonology 2, Kiev

Oesa Regional Clinical Hospital, Odesa

Poltava Regional Clinical Antituberculosis Dispancery, Poltava

Royal Brompton Hospital, London

The Medicines Evaluation Unit, Manchester